IPHA
Innate Pharma
$1.52
+$0.04 (+2.7%)Oct 28, 2026
Key metrics
The numbers that frame IPHA today
- Market cap
- $142.62M
- Gross margin
- 100%
- EV / Sales
- 14.1
- ROIC
- -174.4%
- Div yield
- 0%
- 52wk Low
- $1.17
- 52wk High
- $2.71
Growth
Revenue and earnings trend for IPHA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about IPHA
Is Innate Pharma a good buy?
No. Innate Pharma has weak quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Innate Pharma is selling at a very high price.
What is the market capitalization of IPHA?
Innate Pharma's market capitalization is $142.62M.
What is the 52-week high for IPHA stock?
The 52-week high for Innate Pharma is $2.71. The current close of $1.52 is 43.9% below that high.
What is the 52-week low for IPHA stock?
The 52-week low for Innate Pharma is $1.17. The current close of $1.52 is 29.9% above that low.
Does IPHA stock pay dividends?
Innate Pharma does not currently show a dividend per share in the company data.